Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:22:51 2024-03-28 pm EDT 5-day change 1st Jan Change
19.6 USD -1.95% Intraday chart for Kiniksa Pharmaceuticals, Ltd. -0.91% +11.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kiniksa Pharmaceuticals' Q4 Earnings, Revenue Increase MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q4 Revenue $83.4M, vs. Street Est of $72.3M MT
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024 CI
Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 01:30 PM
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Oct 31, 2023
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q3 Revenue $67M, vs. Street Est of $64.4M MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023 CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Insider Sell: Kiniksa Pharmaceuticals MT
Sector Update: Health Care Stocks Steady in Late Afternoon Trading MT
Sector Update: Health Care MT
Kiniksa Pharmaceuticals' Shares Rise as Q2 Net Income, Revenue Advance MT
Top Midday Gainers MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating MT
- (KNSA) KINIKSA PHARMACEUTICALS Q2 EPS $0.21 MT
Transcript : Kiniksa Pharmaceuticals, Ltd., Q2 2023 Earnings Call, Jul 25, 2023
Kiniksa Pharmaceuticals Q2 Net Income, Revenue Gain MT
(KNSA) KINIKSA PHARMACEUTICALS Sees Q3 EPS $0.21 MT
Earnings Flash (KNSA) KINIKSA PHARMACEUTICALS Reports Q2 Revenue $71.5M, vs. Street Est of $52.2M MT
Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for 2023 CI
Kiniksa Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Kiniksa Pharmaceuticals, Ltd.(NasdaqGS:KNSA) dropped from Russell 2000 Growth Index CI
Chart Kiniksa Pharmaceuticals, Ltd.
More charts
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.99 USD
Average target price
27.8 USD
Spread / Average Target
+39.07%
Consensus